טוען...
High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma
Tumor-specific mutations can result in immunogenic neoantigens, both of which have been correlated with responsiveness to immune checkpoint inhibitors in highly mutagenic cancers. However, early results of single-agent checkpoint inhibitors in multiple myeloma (MM) have been underwhelming. Therefore...
שמור ב:
| הוצא לאור ב: | Blood Cancer J |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Nature Publishing Group
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5709757/ https://ncbi.nlm.nih.gov/pubmed/28937974 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2017.94 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|